2064-2065 / 2351
Tumor cell cytoplasmic membrane
Monoclonal
Antibodies
Cetuximab
Panitumumab
Zalutumumab
Tyrosine kinase
Inhibitors
Gefitinib (EGFR)
Erlotinib (EGFR)
Lapatinib (EGFR + HER2)
Afatinib, dacomitinib
(
pan-HER)
Tumor proliferation
EGF receptor
HER1 or EGFR targeting